ResVita Bio

Engineering bacteria to treat skin diseases

[ResVita Bio @Resvita_Bio]

We are very pleased to announce that the FDA has approved RVB-001 for the Rare Pediatric Disease Designation for the treatment of Netherton Syndrome

https://t.co/zRLNz6Sr0P

[Amin Zargar @microbeinfluncr]

We are so excited to work with passionate and driven scientists to deliver life-saving cellular therapies!

https://t.co/zUsJ6qWYBr

[Amin Zargar @microbeinfluncr]

On #RareDiseaseDay, I'm excited to announce a new company out of the .@jaykeasling lab, @Resvita_Bio, that seeks to engineer skin probiotics to treat skin diseases. Our first disease target is Netherton Syndrome, a rare pediatric disease with no FDA-approved treatment.